On 1 April 2024, the UK and US signed a memorandum of understanding on the science of AI safety. This partnership is the first of its kind and will see the two countries work together to assess risks and develop safety tests for the most advanced AI models.
Following their announcement of cooperation at the
Faegre Drinker Biddle & Reath
Faegre Drinker Biddle & Reath LLP is an international firm providing a range of services including litigation, regulation, and business services to companies of all sizes.
Website:
https://enforcementhighlights.com/
Faegre Drinker Biddle & Reath Blogs
Blog Authors
Latest from Faegre Drinker Biddle & Reath
Make your Company a Hard Target for Job Scams
Your company’s talent is its lifeblood. Job postings for qualified individuals and other recruitment activities are vital to its operations. What happens, then, when scammers disrupt your business by conducting phishing schemes to trick individuals into applying for nonexistent jobs you did not post with the objective of stealing their personally identifiable information? In the…
In Case You Missed It – Winter 2024
Catch up on the latest developments of interest for product manufacturers. Here’s a quarterly compilation of the most popular blog posts on Faegre Drinker on Products. Michigan Repeals Pharma Immunity Provision By Jacqueline E. McDonnell Michigan recently signed into law a repeal of the immunity provision under its Product Liability Act, presenting a new litigation…
Attention to Detail — and the Defense — Prevails in Two Recent Cases
Two recent decisions emphasize the necessity of precisely examining a plaintiff’s complaint for potential defenses while keeping each element of the TCPA in mind. First, in Hulce v. Zipongo, Inc., No. 23-C-0159, 2024 WL 1251108 (E.D. Wis. Mar. 18, 2024), the United States District Court for the Eastern District of Wisconsin granted the defendant’s motion…
ERISA Moments Ep. 22: An Update on the DOL Fiduciary Proposals: A Race to the Finish
Take a quick dive into the exciting world of ERISA with Faegre Drinker benefits and executive compensation attorneys Fred Reish and Brad Campbell. In this quick-hit series of updates, Fred and Brad offer a high-level view of current trends and recent ERISA developments. See the newest episode, An Update on the DOL Fiduciary Proposals: A…
From Concept to Commerce: The Art of Trademark Specimens of Use
In the world of trademarks, specimens of use (or proof of use) play a crucial role in obtaining and maintaining a trademark registration with the United States Patent and Trademark Office (“USPTO”). In this blog post, we’ll delve into the types of specimens that are accepted by the USPTO (hint: they’re not alien artifacts!), the…
Can ChatGPT be Your ERISA Counsel?
Is ChatGPT sufficiently reliable to provide advice on employee benefits matters? Not yet, but ChatGPT and generative Artificial Intelligence may likely be useful tools for employee benefits attorneys in the future.[1]
As it is late March, we asked ChatGPT 3.5 to solve a common issue: an individual made deferrals above the Internal Revenue Code…
ERISA Moments Ep. 21: The DOL Fiduciary Proposals and Rollover Recommendations
Take a quick dive into the exciting world of ERISA with Faegre Drinker benefits and executive compensation attorneys Fred Reish and Brad Campbell. In this quick-hit series of updates, Fred and Brad offer a high-level view of current trends and recent ERISA developments. See the newest episode, The DOL Fiduciary Proposals and Rollover Recommendations, below.
Missing the Mark: Summary Judgment Granted Where Plaintiff’s Experts Opine on Defect but Fail to Support Causation
Product liability claims require proof of causation. To be sure, they also require proof of some defect in the product and/or its accompanying warnings and product literature. But defect and causation are separate elements of a prima facie claim, and both must be established – usually, through expert testimony. As we have discussed on multiple…
FDA Publishes New Artificial Intelligence & Medical Products White Paper
On March 15, the United States Food & Drug Administration published a white paper entitled “Artificial Intelligence & Medical Products: How CBER, CDER, CDRH, and OCP are Working Together.” FDA announced the paper by sharing a short letter from Commissioner Califf, where he reaffirmed the Agency’s commitment to “promoting the responsible and ethical development, deployment,…